This webinar will focus on how we may improve the clinical outcome of advanced-stage cancers by i) predicting the therapeutic efficacy of standard-of-care drugs through -omics-based profiling and ii) integrating in silico prediction and single-cell -omics-based screening with cell-based and molecular genetics-based functional assays in in vitro and ex vivo model systems to establish novel agents as potent drug candidates to circumvent emerging drug resistance.

This webinar offers a comprehensive program aimed at enhancing the clinical outcomes of advanced-stage cancers through cutting-edge methodologies. It begins by exploring the predictive power of -omics-based profiling in determining the therapeutic effectiveness of standard-of-care drugs. Attendees will delve into how advancements in this field can revolutionize treatment strategies by providing personalized insights into patient responses.
The program then shifts focus to the integration of in silico prediction techniques with single-cell -omics-based screening, coupled with cell-based and molecular genetics-based functional assays. This multifaceted approach, conducted in vitro and ex vivo model systems, facilitates the identification and validation of novel agents with potent therapeutic potential. By leveraging these innovative methodologies, the webinar aims to address the challenge of emerging drug resistance in advanced-stage cancers.
Overall, participants will gain a deep understanding of how the convergence of predictive profiling, advanced screening methods, and functional assays can pave the way for the development of more effective therapeutic interventions, ultimately improving clinical outcomes for patients facing advanced-stage cancers.

Amit Kumar Mitra

Assistant Professor in the Department of Drug Discovery and Development

Auburn University, Harrison College of Pharmacy